Bank of New York Mellon Corp Purchases 111,989 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Bank of New York Mellon Corp boosted its holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 33.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 450,261 shares of the company’s stock after buying an additional 111,989 shares during the period. Bank of New York Mellon Corp’s holdings in Taysha Gene Therapies were worth $779,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Intech Investment Management LLC purchased a new position in shares of Taysha Gene Therapies in the third quarter worth $85,000. Charles Schwab Investment Management Inc. increased its holdings in Taysha Gene Therapies by 7.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 462,867 shares of the company’s stock worth $930,000 after buying an additional 33,123 shares in the last quarter. MetLife Investment Management LLC raised its position in Taysha Gene Therapies by 81.9% in the 3rd quarter. MetLife Investment Management LLC now owns 76,037 shares of the company’s stock worth $153,000 after buying an additional 34,243 shares during the last quarter. State Street Corp lifted its stake in Taysha Gene Therapies by 4.5% during the 3rd quarter. State Street Corp now owns 3,469,068 shares of the company’s stock valued at $6,973,000 after acquiring an additional 150,647 shares during the period. Finally, Wellington Management Group LLP purchased a new stake in shares of Taysha Gene Therapies during the 3rd quarter valued at about $931,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ TSHA opened at $1.77 on Wednesday. Taysha Gene Therapies, Inc. has a 12-month low of $1.19 and a 12-month high of $4.32. The firm has a market capitalization of $362.85 million, a price-to-earnings ratio of 2.81 and a beta of 0.91. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. The firm has a 50 day moving average of $1.64 and a 200 day moving average of $1.92.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. The firm had revenue of $2.02 million during the quarter, compared to the consensus estimate of $2.05 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. On average, research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.

Analyst Upgrades and Downgrades

TSHA has been the subject of several research reports. Chardan Capital reissued a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and set a $6.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, February 27th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $6.63.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.